Genmab A/S (OTCMKTS:GNMSF) Posts Quarterly Earnings Results, Beats Expectations By $5.24 EPS

Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings data on Wednesday. The company reported $5.70 EPS for the quarter, beating the consensus estimate of $0.46 by $5.24, Zacks reports. Genmab A/S had a return on equity of 17.73% and a net margin of 23.49%.

Genmab A/S Trading Up 8.2 %

Shares of GNMSF traded up $15.78 during midday trading on Friday, hitting $207.62. 30 shares of the company’s stock traded hands, compared to its average volume of 6,895. The firm’s fifty day moving average is $206.28 and its 200-day moving average is $230.43. Genmab A/S has a 1 year low of $186.61 and a 1 year high of $323.02. The stock has a market capitalization of $13.72 billion, a price-to-earnings ratio of 19.96 and a beta of 1.04.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.